{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-030565","form_type":"8-K/A","ticker":"BVS","cik":"0001665988","company_name":"Bioventus Inc.","filed_at":"2022-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.632818+00:00","generated_at":"2026-06-21T15:05:56.658548+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Bioventus amends Q3 results with $189M impairment; cuts FY2022 guidance","bullets":["Net loss of $145.7M ($1.76 loss per share) vs $2.3M loss in prior year; includes $189.2M non-cash impairment.","Net sales of $128.7M, +18.2% YoY; organic sales down 0.5%.","FY2022 guidance cut: net sales now $517-522M (prev $547.5-562.5M); Adj. EBITDA $75-79M (prev $94-104M).","Non-GAAP EPS guidance lowered to $0.20-0.25 from $0.47-0.57.","Company discontinued development of MOTYS drug candidate."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-030565","json":"https://secwatch.observer/filing/0001628280-22-030565.json","markdown":"https://secwatch.observer/filing/0001628280-22-030565.md","text":"https://secwatch.observer/filing/0001628280-22-030565.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/0001628280-22-030565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/bvs-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T15:05:56.658548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2f7ef75b523605bb4ca20104d41f7b6e7ed00fad","claim":"Bioventus Inc. reported financial results for the nine months ended October 1, 2022.","evidence_excerpt":"amended its previously announced financial results for the three and nine months ended October 1, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/0001628280-22-030565-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine months ended October 1, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7924a6582e23c0db1a658b14c56e6c7eacd5c848","claim":"Bioventus Inc. reported the three months ended October 1, 2022 results: revenue $128.7 million, net income $145.7 million, EPS $1.76.","evidence_excerpt":"• Net Sales of $128.7 million, up $19.8 million, or 18.2%, year-over-year as reported (19.1% constant currency*) and down (0.5%) organically* (0.3% constant currency*) • Net Loss of $145.7 million, compared to Net Loss of $2.3 million in prior-year period • Adjusted EBITDA* of $21.0 million, compared to $21.3 million in prior-year period • Loss per share of Class A common stock of $1.76, compared to $0.03 in prior-year period • Non-GAAP earnings per share of Class A common stock* of $0.06, compared to $0.19 in prior-year period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/0001628280-22-030565-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended October 1, 2022"},{"label":"Revenue","value":"$128.7 million"},{"label":"Net income","value":"$145.7 million"},{"label":"EPS","value":"$1.76"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"853ce18b6556e3e86d3c2456d49f77dc6304a561","claim":"Bioventus Inc. reported the twelve months ending December 31, 2022 results: revenue $517 million to $522 million, EPS $0.20 to $0.25. Guidance lowered.","evidence_excerpt":"• Net sales of $517 million to $522 million, representing year-over-year growth of approximately 20% to 21%, representing an update to the prior guidance of $547.5 million to $562.5 million. • Adjusted EBITDA* of $75 million to $79 million, compared to $80.8 million for the year ended December 31, 2021, and representing an update from the prior guidance of $94 million to $104 million. • Non-GAAP EPS* of $0.20 to $0.25, compared to $0.75 for the year ended December 31, 2021, and representing an update from the prior guidance of $0.47 to $0.57.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1665988/000162828022030565/0001628280-22-030565-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the twelve months ending December 31, 2022"},{"label":"Revenue","value":"$517 million to $522 million"},{"label":"EPS","value":"$0.20 to $0.25"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}